Onconova Therapeutics Insiders

ONTXDelisted Stock  USD 1.02  0.04  3.77%   
Onconova Therapeutics employs about 16 people. The company is managed by 5 executives with a total tenure of roughly 38 years, averaging almost 7.0 years of service per executive, having 3.2 employees per reported executive. Break down of Onconova Therapeutics' management performance can provide insight into the company performance.
  
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

Onconova Therapeutics Management Team Effectiveness

The company has return on total asset (ROA) of (0.3807) % which means that it has lost $0.3807 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.843) %, meaning that it created substantial loss on money invested by shareholders. Onconova Therapeutics' management efficiency ratios could be used to measure how well Onconova Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.

Onconova Therapeutics Workforce Comparison

Onconova Therapeutics is rated below average in number of employees category among its peers. The total workforce of Health Care industry is now estimated at about 609. Onconova Therapeutics holds roughly 16.0 in number of employees claiming about 2.63% of equities under Health Care industry.

Onconova Therapeutics Insider Trading

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Onconova Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Onconova Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Onconova Therapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Onconova Therapeutics Notable Stakeholders

An Onconova Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Onconova Therapeutics often face trade-offs trying to please all of them. Onconova Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Onconova Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.

About Onconova Therapeutics Management Performance

The success or failure of an entity such as Onconova Therapeutics often depends on how effective the management is. Onconova Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Onconova management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Onconova management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer. Onconova Therapeutics, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania. Onconova Therapeutic operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 14 people.
Please note, the imprecision that can be found in Onconova Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Onconova Therapeutics. Check Onconova Therapeutics' Beneish M Score to see the likelihood of Onconova Therapeutics' management manipulating its earnings.

Onconova Therapeutics Workforce Analysis

Traditionally, organizations such as Onconova Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Onconova Therapeutics within its industry.

Onconova Therapeutics Manpower Efficiency

Return on Onconova Therapeutics Manpower

Revenue Per Employee14.1B
Revenue Per Executive45.2B
Net Loss Per Employee1.2T
Net Loss Per Executive3.8T
Working Capital Per Employee2M
Working Capital Per Executive6.3M
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.

Other Consideration for investing in Onconova Stock

If you are still planning to invest in Onconova Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Onconova Therapeutics' history and understand the potential risks before investing.
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
CEOs Directory
Screen CEOs from public companies around the world
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Transaction History
View history of all your transactions and understand their impact on performance